| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| T-Lymphocytes | 26 | 2025 | 1738 | 4.050 |
Why?
|
| Glioblastoma | 14 | 2023 | 363 | 3.880 |
Why?
|
| Immunotherapy, Adoptive | 19 | 2025 | 897 | 3.320 |
Why?
|
| Receptor, ErbB-2 | 13 | 2025 | 515 | 2.550 |
Why?
|
| Brain Neoplasms | 16 | 2023 | 1378 | 2.460 |
Why?
|
| Receptors, Antigen, T-Cell | 13 | 2020 | 491 | 2.280 |
Why?
|
| Immunotherapy | 13 | 2019 | 745 | 2.000 |
Why?
|
| Interleukin-13 Receptor alpha2 Subunit | 5 | 2018 | 20 | 1.850 |
Why?
|
| Sarcoma | 3 | 2025 | 208 | 1.300 |
Why?
|
| Adoptive Transfer | 6 | 2015 | 238 | 1.280 |
Why?
|
| Immunological Synapses | 2 | 2025 | 29 | 1.020 |
Why?
|
| Medulloblastoma | 5 | 2020 | 570 | 0.890 |
Why?
|
| Membrane Microdomains | 1 | 2025 | 61 | 0.880 |
Why?
|
| Molecular Dynamics Simulation | 1 | 2025 | 120 | 0.850 |
Why?
|
| Antigens, Neoplasm | 4 | 2020 | 401 | 0.840 |
Why?
|
| Neoplasms | 7 | 2025 | 2955 | 0.840 |
Why?
|
| Tumor Escape | 4 | 2016 | 63 | 0.750 |
Why?
|
| Antigenic Variation | 2 | 2018 | 42 | 0.700 |
Why?
|
| Tumor Microenvironment | 4 | 2016 | 688 | 0.690 |
Why?
|
| Liver Diseases | 2 | 2019 | 384 | 0.670 |
Why?
|
| Receptor, EphA2 | 2 | 2018 | 28 | 0.660 |
Why?
|
| Muscle Neoplasms | 1 | 2020 | 21 | 0.660 |
Why?
|
| Cancer Vaccines | 4 | 2020 | 188 | 0.640 |
Why?
|
| Flow Cytometry | 6 | 2017 | 791 | 0.640 |
Why?
|
| Blood Specimen Collection | 1 | 2019 | 47 | 0.610 |
Why?
|
| Mice, SCID | 9 | 2023 | 601 | 0.590 |
Why?
|
| Cerebellar Neoplasms | 3 | 2020 | 459 | 0.570 |
Why?
|
| Cell Line, Tumor | 15 | 2025 | 3681 | 0.550 |
Why?
|
| T-Lymphocytes, Cytotoxic | 6 | 2017 | 519 | 0.540 |
Why?
|
| Leukocytes, Mononuclear | 4 | 2022 | 354 | 0.530 |
Why?
|
| Rhabdomyosarcoma | 1 | 2020 | 214 | 0.530 |
Why?
|
| Xenograft Model Antitumor Assays | 11 | 2025 | 990 | 0.520 |
Why?
|
| Cell- and Tissue-Based Therapy | 2 | 2017 | 162 | 0.520 |
Why?
|
| Vidarabine | 2 | 2024 | 82 | 0.500 |
Why?
|
| Transplantation Conditioning | 3 | 2018 | 304 | 0.500 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 5 | 2023 | 1199 | 0.500 |
Why?
|
| Humans | 64 | 2025 | 132061 | 0.490 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2020 | 1297 | 0.490 |
Why?
|
| Antibodies, Monoclonal | 3 | 2014 | 1028 | 0.490 |
Why?
|
| Hematologic Neoplasms | 4 | 2025 | 295 | 0.490 |
Why?
|
| Viral Matrix Proteins | 2 | 2015 | 109 | 0.480 |
Why?
|
| Microspheres | 1 | 2015 | 73 | 0.470 |
Why?
|
| Immediate-Early Proteins | 1 | 2015 | 58 | 0.460 |
Why?
|
| Immunophenotyping | 1 | 2015 | 342 | 0.440 |
Why?
|
| Central Nervous System Neoplasms | 2 | 2014 | 212 | 0.420 |
Why?
|
| Phosphoproteins | 1 | 2015 | 442 | 0.400 |
Why?
|
| Lymphoma | 2 | 2024 | 331 | 0.370 |
Why?
|
| Mice | 22 | 2025 | 18507 | 0.370 |
Why?
|
| Membrane Proteins | 1 | 2019 | 1610 | 0.360 |
Why?
|
| Cytotoxicity, Immunologic | 4 | 2025 | 264 | 0.360 |
Why?
|
| Animals | 28 | 2025 | 34881 | 0.350 |
Why?
|
| Chemotaxis | 1 | 2011 | 62 | 0.350 |
Why?
|
| Neoplastic Stem Cells | 2 | 2013 | 347 | 0.350 |
Why?
|
| Osteosarcoma | 2 | 2015 | 262 | 0.340 |
Why?
|
| Bone Neoplasms | 1 | 2015 | 444 | 0.330 |
Why?
|
| Recombinant Fusion Proteins | 4 | 2017 | 762 | 0.320 |
Why?
|
| Antigens, Viral | 1 | 2012 | 437 | 0.320 |
Why?
|
| T-Cell Antigen Receptor Specificity | 1 | 2010 | 55 | 0.320 |
Why?
|
| Cytomegalovirus | 3 | 2017 | 259 | 0.310 |
Why?
|
| Tumor Cells, Cultured | 5 | 2020 | 1045 | 0.300 |
Why?
|
| CD28 Antigens | 2 | 2025 | 76 | 0.300 |
Why?
|
| Yellow Fever Vaccine | 1 | 2009 | 42 | 0.300 |
Why?
|
| Antibodies, Neoplasm | 1 | 2008 | 59 | 0.290 |
Why?
|
| Yellow Fever | 1 | 2009 | 76 | 0.290 |
Why?
|
| Triple Negative Breast Neoplasms | 2 | 2025 | 270 | 0.290 |
Why?
|
| Glioma | 4 | 2017 | 529 | 0.280 |
Why?
|
| Male | 23 | 2025 | 64920 | 0.280 |
Why?
|
| Child | 19 | 2025 | 25789 | 0.280 |
Why?
|
| Endothelial Cells | 1 | 2011 | 527 | 0.270 |
Why?
|
| beta-Thalassemia | 1 | 2007 | 27 | 0.270 |
Why?
|
| Lymphocyte Depletion | 2 | 2024 | 125 | 0.260 |
Why?
|
| Treatment Outcome | 7 | 2024 | 13028 | 0.260 |
Why?
|
| Leukemia | 2 | 2024 | 370 | 0.260 |
Why?
|
| Oncogenic Viruses | 1 | 2006 | 17 | 0.250 |
Why?
|
| Cell Proliferation | 5 | 2018 | 2508 | 0.250 |
Why?
|
| Cell Transformation, Viral | 1 | 2006 | 97 | 0.250 |
Why?
|
| Antineoplastic Agents | 3 | 2016 | 1824 | 0.240 |
Why?
|
| Signal Transduction | 2 | 2025 | 4703 | 0.240 |
Why?
|
| Endoglin | 1 | 2025 | 32 | 0.240 |
Why?
|
| Tumor Virus Infections | 1 | 2006 | 139 | 0.230 |
Why?
|
| Genome, Viral | 1 | 2006 | 179 | 0.230 |
Why?
|
| Pneumococcal Infections | 1 | 2007 | 277 | 0.230 |
Why?
|
| Zona Pellucida Glycoproteins | 1 | 2025 | 8 | 0.230 |
Why?
|
| Streptococcus pneumoniae | 1 | 2007 | 381 | 0.230 |
Why?
|
| Cyclophosphamide | 2 | 2024 | 428 | 0.230 |
Why?
|
| Tumor Necrosis Factor Receptor Superfamily, Member 9 | 1 | 2025 | 26 | 0.230 |
Why?
|
| Vaccines | 1 | 2010 | 382 | 0.230 |
Why?
|
| Lymphocyte Activation | 4 | 2025 | 678 | 0.220 |
Why?
|
| Graft Rejection | 1 | 2008 | 559 | 0.220 |
Why?
|
| Female | 20 | 2025 | 70710 | 0.220 |
Why?
|
| CD8-Positive T-Lymphocytes | 2 | 2024 | 442 | 0.210 |
Why?
|
| Alemtuzumab | 2 | 2018 | 88 | 0.210 |
Why?
|
| Antigens, CD19 | 3 | 2021 | 183 | 0.210 |
Why?
|
| Adolescent | 12 | 2025 | 20562 | 0.210 |
Why?
|
| Child, Preschool | 12 | 2025 | 14751 | 0.210 |
Why?
|
| Anemia, Sickle Cell | 1 | 2007 | 329 | 0.210 |
Why?
|
| Adult | 9 | 2024 | 31567 | 0.200 |
Why?
|
| Mice, Inbred NOD | 3 | 2023 | 314 | 0.200 |
Why?
|
| Cord Blood Stem Cell Transplantation | 1 | 2023 | 48 | 0.190 |
Why?
|
| Oncolytic Viruses | 1 | 2023 | 76 | 0.190 |
Why?
|
| Oncolytic Virotherapy | 1 | 2023 | 89 | 0.190 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 1 | 2024 | 153 | 0.190 |
Why?
|
| Transduction, Genetic | 5 | 2020 | 293 | 0.180 |
Why?
|
| Single-Cell Analysis | 1 | 2024 | 347 | 0.170 |
Why?
|
| Clinical Trials, Phase I as Topic | 1 | 2020 | 69 | 0.160 |
Why?
|
| Leukemia, B-Cell | 1 | 2020 | 25 | 0.160 |
Why?
|
| Cerebrospinal Fluid | 1 | 2020 | 98 | 0.160 |
Why?
|
| Transplantation, Autologous | 1 | 2020 | 286 | 0.160 |
Why?
|
| Middle Aged | 5 | 2024 | 28964 | 0.160 |
Why?
|
| Freezing | 1 | 2019 | 28 | 0.160 |
Why?
|
| Immunologic Memory | 1 | 2021 | 196 | 0.160 |
Why?
|
| Prospective Studies | 3 | 2024 | 6567 | 0.160 |
Why?
|
| Remission Induction | 1 | 2020 | 307 | 0.160 |
Why?
|
| Biopsy | 2 | 2020 | 1284 | 0.150 |
Why?
|
| Infant | 8 | 2025 | 13064 | 0.150 |
Why?
|
| Transgenes | 2 | 2020 | 335 | 0.150 |
Why?
|
| Protein Stability | 1 | 2019 | 169 | 0.150 |
Why?
|
| Irritable Bowel Syndrome | 1 | 2022 | 223 | 0.150 |
Why?
|
| HEK293 Cells | 3 | 2020 | 799 | 0.150 |
Why?
|
| Genetic Therapy | 2 | 2014 | 719 | 0.150 |
Why?
|
| Bone Marrow | 1 | 2020 | 327 | 0.140 |
Why?
|
| Follow-Up Studies | 6 | 2025 | 5409 | 0.140 |
Why?
|
| Ependymoma | 1 | 2020 | 173 | 0.140 |
Why?
|
| Cytokines | 3 | 2020 | 1358 | 0.140 |
Why?
|
| Osteopontin | 1 | 2018 | 52 | 0.140 |
Why?
|
| Neoplasm Transplantation | 2 | 2016 | 382 | 0.140 |
Why?
|
| Wiskott-Aldrich Syndrome | 1 | 2017 | 23 | 0.140 |
Why?
|
| Neoplasms, Experimental | 2 | 2010 | 217 | 0.140 |
Why?
|
| Granulomatous Disease, Chronic | 1 | 2018 | 70 | 0.140 |
Why?
|
| Choroid Plexus Neoplasms | 1 | 2017 | 17 | 0.140 |
Why?
|
| Aged | 4 | 2024 | 21406 | 0.140 |
Why?
|
| Severe Combined Immunodeficiency | 2 | 2008 | 106 | 0.130 |
Why?
|
| Vimentin | 1 | 2017 | 67 | 0.130 |
Why?
|
| Molecular Imaging | 1 | 2017 | 63 | 0.130 |
Why?
|
| Neoplasm Metastasis | 2 | 2020 | 719 | 0.130 |
Why?
|
| Herpesvirus 4, Human | 2 | 2017 | 670 | 0.130 |
Why?
|
| Cells, Cultured | 3 | 2017 | 3036 | 0.130 |
Why?
|
| Adenoviridae | 2 | 2017 | 595 | 0.120 |
Why?
|
| Protein Binding | 2 | 2020 | 1729 | 0.120 |
Why?
|
| Proto-Oncogene Proteins B-raf | 1 | 2018 | 221 | 0.120 |
Why?
|
| Transplantation, Homologous | 1 | 2018 | 652 | 0.120 |
Why?
|
| Interleukin-13 | 1 | 2016 | 94 | 0.120 |
Why?
|
| Microtubule-Associated Proteins | 1 | 2017 | 257 | 0.120 |
Why?
|
| Polystyrenes | 1 | 2015 | 10 | 0.120 |
Why?
|
| Protein Multimerization | 1 | 2016 | 151 | 0.120 |
Why?
|
| Autoimmune Diseases | 1 | 2018 | 271 | 0.120 |
Why?
|
| Genetic Engineering | 1 | 2016 | 164 | 0.120 |
Why?
|
| Color | 1 | 2015 | 34 | 0.120 |
Why?
|
| Receptors, Cell Surface | 1 | 2017 | 450 | 0.120 |
Why?
|
| Survival Rate | 4 | 2017 | 2192 | 0.120 |
Why?
|
| Neuroectodermal Tumors | 1 | 2015 | 13 | 0.120 |
Why?
|
| Portraits as Topic | 1 | 2015 | 3 | 0.110 |
Why?
|
| Neurodegenerative Diseases | 1 | 2018 | 279 | 0.110 |
Why?
|
| Histiocytosis, Langerhans-Cell | 1 | 2018 | 241 | 0.110 |
Why?
|
| Carcinoma | 1 | 2017 | 299 | 0.110 |
Why?
|
| Maximum Tolerated Dose | 1 | 2015 | 174 | 0.110 |
Why?
|
| In Situ Hybridization | 2 | 2013 | 468 | 0.110 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2015 | 1131 | 0.110 |
Why?
|
| Paraneoplastic Syndromes | 1 | 2014 | 17 | 0.110 |
Why?
|
| Apoptosis | 2 | 2018 | 1892 | 0.110 |
Why?
|
| Separase | 1 | 2014 | 28 | 0.110 |
Why?
|
| Recurrence | 2 | 2015 | 1470 | 0.110 |
Why?
|
| Leukocytes | 1 | 2015 | 209 | 0.110 |
Why?
|
| Fluorescent Dyes | 1 | 2015 | 264 | 0.110 |
Why?
|
| Autophagy | 1 | 2017 | 426 | 0.110 |
Why?
|
| Antibodies | 1 | 2015 | 364 | 0.110 |
Why?
|
| Astrocytes | 1 | 2017 | 269 | 0.110 |
Why?
|
| Sarcoma, Ewing | 1 | 2015 | 116 | 0.100 |
Why?
|
| Adenocarcinoma | 1 | 2021 | 1014 | 0.100 |
Why?
|
| Immune System Diseases | 1 | 2014 | 52 | 0.100 |
Why?
|
| Antigens, CD1d | 1 | 2013 | 21 | 0.100 |
Why?
|
| Neoplasm Proteins | 1 | 2017 | 697 | 0.100 |
Why?
|
| NFI Transcription Factors | 1 | 2013 | 50 | 0.100 |
Why?
|
| Synapses | 1 | 2017 | 456 | 0.100 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 2 | 2012 | 822 | 0.100 |
Why?
|
| Positron-Emission Tomography | 1 | 2015 | 308 | 0.100 |
Why?
|
| Retroviridae | 2 | 2012 | 193 | 0.100 |
Why?
|
| Natural Killer T-Cells | 1 | 2013 | 84 | 0.090 |
Why?
|
| Cardiovascular Diseases | 1 | 2025 | 2092 | 0.090 |
Why?
|
| Disease-Free Survival | 2 | 2017 | 955 | 0.090 |
Why?
|
| T-Lymphocyte Subsets | 2 | 2024 | 206 | 0.090 |
Why?
|
| Cell Nucleus | 1 | 2014 | 587 | 0.090 |
Why?
|
| Up-Regulation | 1 | 2014 | 876 | 0.090 |
Why?
|
| Receptors, Antigen | 1 | 2011 | 33 | 0.090 |
Why?
|
| Macrophage Migration-Inhibitory Factors | 1 | 2011 | 15 | 0.090 |
Why?
|
| Cell Separation | 1 | 2012 | 223 | 0.090 |
Why?
|
| Biomarkers, Tumor | 2 | 2017 | 1658 | 0.090 |
Why?
|
| Chemokine CCL5 | 1 | 2011 | 52 | 0.090 |
Why?
|
| Nanoshells | 1 | 2010 | 13 | 0.090 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2018 | 814 | 0.080 |
Why?
|
| Young Adult | 4 | 2024 | 9956 | 0.080 |
Why?
|
| Retrospective Studies | 6 | 2025 | 17419 | 0.080 |
Why?
|
| Phototherapy | 1 | 2010 | 39 | 0.080 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 2019 | 985 | 0.080 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2015 | 808 | 0.080 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 1 | 2011 | 140 | 0.080 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2013 | 633 | 0.080 |
Why?
|
| Disease Models, Animal | 4 | 2025 | 4688 | 0.080 |
Why?
|
| Biological Assay | 1 | 2010 | 111 | 0.080 |
Why?
|
| Mice, Inbred ICR | 1 | 2010 | 151 | 0.080 |
Why?
|
| Combined Modality Therapy | 1 | 2013 | 1294 | 0.080 |
Why?
|
| Cytomegalovirus Infections | 1 | 2012 | 223 | 0.080 |
Why?
|
| Tumor Burden | 1 | 2010 | 246 | 0.080 |
Why?
|
| Liver Neoplasms | 1 | 2019 | 1381 | 0.070 |
Why?
|
| Transplantation Chimera | 1 | 2008 | 43 | 0.070 |
Why?
|
| Cell Culture Techniques | 1 | 2010 | 285 | 0.070 |
Why?
|
| Lymphocyte Transfusion | 1 | 2008 | 58 | 0.070 |
Why?
|
| Th2 Cells | 1 | 2009 | 188 | 0.070 |
Why?
|
| Cell Membrane | 1 | 2010 | 470 | 0.070 |
Why?
|
| Th1 Cells | 1 | 2009 | 156 | 0.070 |
Why?
|
| Immunohistochemistry | 2 | 2013 | 1694 | 0.070 |
Why?
|
| Models, Biological | 1 | 2013 | 1443 | 0.070 |
Why?
|
| Living Donors | 1 | 2008 | 116 | 0.070 |
Why?
|
| Lung Neoplasms | 1 | 2017 | 1538 | 0.070 |
Why?
|
| Brain | 3 | 2018 | 3183 | 0.070 |
Why?
|
| Metabolic Diseases | 1 | 2008 | 139 | 0.070 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2015 | 2172 | 0.060 |
Why?
|
| Fatal Outcome | 1 | 2007 | 370 | 0.060 |
Why?
|
| Gene Expression | 2 | 2022 | 1558 | 0.060 |
Why?
|
| MicroRNAs | 1 | 2013 | 918 | 0.060 |
Why?
|
| Antigen-Presenting Cells | 1 | 2007 | 133 | 0.060 |
Why?
|
| Immunity, Innate | 1 | 2009 | 413 | 0.060 |
Why?
|
| Cell Communication | 1 | 2007 | 187 | 0.060 |
Why?
|
| Cohort Studies | 1 | 2015 | 5164 | 0.060 |
Why?
|
| Prognosis | 3 | 2025 | 5009 | 0.060 |
Why?
|
| Single-Chain Antibodies | 1 | 2025 | 44 | 0.060 |
Why?
|
| Pediatrics | 1 | 2014 | 1213 | 0.060 |
Why?
|
| Monocytes | 1 | 2007 | 342 | 0.060 |
Why?
|
| Acute Disease | 1 | 2007 | 1160 | 0.050 |
Why?
|
| Immunocompromised Host | 1 | 2006 | 306 | 0.050 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2008 | 553 | 0.050 |
Why?
|
| Programmed Cell Death 1 Receptor | 1 | 2025 | 130 | 0.050 |
Why?
|
| B7-H1 Antigen | 1 | 2025 | 126 | 0.050 |
Why?
|
| Coculture Techniques | 2 | 2017 | 235 | 0.050 |
Why?
|
| Graft vs Host Disease | 1 | 2008 | 629 | 0.050 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2015 | 3833 | 0.050 |
Why?
|
| Busulfan | 1 | 2023 | 44 | 0.050 |
Why?
|
| Mice, Transgenic | 2 | 2020 | 2445 | 0.050 |
Why?
|
| Neutropenia | 1 | 2024 | 205 | 0.050 |
Why?
|
| Egypt | 1 | 2022 | 30 | 0.050 |
Why?
|
| Thrombocytopenia | 1 | 2024 | 233 | 0.050 |
Why?
|
| Biological Products | 1 | 2024 | 137 | 0.050 |
Why?
|
| RNA, Messenger | 2 | 2022 | 2674 | 0.050 |
Why?
|
| Ghrelin | 1 | 2022 | 56 | 0.050 |
Why?
|
| TRPV Cation Channels | 1 | 2022 | 46 | 0.050 |
Why?
|
| Infant, Newborn | 3 | 2019 | 8549 | 0.040 |
Why?
|
| Antiviral Agents | 1 | 2006 | 822 | 0.040 |
Why?
|
| Injections, Intraventricular | 1 | 2020 | 60 | 0.040 |
Why?
|
| Immunity, Cellular | 1 | 2021 | 201 | 0.040 |
Why?
|
| Treatment Failure | 1 | 2021 | 367 | 0.040 |
Why?
|
| Genetic Vectors | 2 | 2014 | 925 | 0.040 |
Why?
|
| Biomarkers | 2 | 2020 | 3406 | 0.040 |
Why?
|
| Drug Delivery Systems | 1 | 2020 | 225 | 0.040 |
Why?
|
| Structure-Activity Relationship | 1 | 2020 | 588 | 0.040 |
Why?
|
| Gene Editing | 1 | 2021 | 208 | 0.040 |
Why?
|
| Chimerism | 1 | 2018 | 29 | 0.040 |
Why?
|
| Guillain-Barre Syndrome | 1 | 2018 | 31 | 0.040 |
Why?
|
| Pancytopenia | 1 | 2018 | 40 | 0.040 |
Why?
|
| Unrelated Donors | 1 | 2018 | 70 | 0.030 |
Why?
|
| Autophagosomes | 1 | 2017 | 30 | 0.030 |
Why?
|
| Oxidoreductases Acting on CH-NH Group Donors | 1 | 2017 | 25 | 0.030 |
Why?
|
| Antigens | 1 | 2017 | 149 | 0.030 |
Why?
|
| Biotechnology | 1 | 2017 | 59 | 0.030 |
Why?
|
| Aldehyde Dehydrogenase | 1 | 2017 | 45 | 0.030 |
Why?
|
| Allografts | 1 | 2017 | 195 | 0.030 |
Why?
|
| History, 21st Century | 1 | 2018 | 272 | 0.030 |
Why?
|
| Gene Silencing | 1 | 2017 | 238 | 0.030 |
Why?
|
| Microscopy | 1 | 2017 | 128 | 0.030 |
Why?
|
| MAP Kinase Signaling System | 1 | 2018 | 309 | 0.030 |
Why?
|
| Clinical Trials as Topic | 1 | 2021 | 1163 | 0.030 |
Why?
|
| Gene Expression Regulation, Neoplastic | 2 | 2014 | 2057 | 0.030 |
Why?
|
| Microfilament Proteins | 1 | 2017 | 282 | 0.030 |
Why?
|
| Genotype | 1 | 2022 | 2697 | 0.030 |
Why?
|
| Rats | 2 | 2013 | 3611 | 0.030 |
Why?
|
| Killer Cells, Natural | 1 | 2017 | 347 | 0.030 |
Why?
|
| Interleukin-13 Receptor alpha1 Subunit | 1 | 2014 | 6 | 0.030 |
Why?
|
| Stem Cell Research | 1 | 2014 | 6 | 0.030 |
Why?
|
| Immunotoxins | 1 | 2014 | 21 | 0.030 |
Why?
|
| Education, Continuing | 1 | 2014 | 31 | 0.030 |
Why?
|
| National Institutes of Health (U.S.) | 1 | 2014 | 136 | 0.030 |
Why?
|
| Genetic Research | 1 | 2014 | 56 | 0.030 |
Why?
|
| Hematopoietic Stem Cells | 1 | 2018 | 550 | 0.030 |
Why?
|
| Chick Embryo | 1 | 2013 | 120 | 0.030 |
Why?
|
| Tissue Array Analysis | 1 | 2013 | 137 | 0.030 |
Why?
|
| Chromatin Immunoprecipitation | 1 | 2013 | 236 | 0.020 |
Why?
|
| Amino Acid Substitution | 1 | 2014 | 409 | 0.020 |
Why?
|
| K562 Cells | 1 | 2012 | 96 | 0.020 |
Why?
|
| Diagnosis, Differential | 1 | 2018 | 1952 | 0.020 |
Why?
|
| Stem Cell Transplantation | 1 | 2014 | 249 | 0.020 |
Why?
|
| Interleukin-2 | 1 | 2012 | 238 | 0.020 |
Why?
|
| Cell Cycle | 1 | 2014 | 611 | 0.020 |
Why?
|
| Seizures | 1 | 2017 | 893 | 0.020 |
Why?
|
| Neuroglia | 1 | 2013 | 212 | 0.020 |
Why?
|
| Antigen Presentation | 1 | 2011 | 117 | 0.020 |
Why?
|
| Killer Cells, Lymphokine-Activated | 1 | 2010 | 10 | 0.020 |
Why?
|
| Microscopy, Atomic Force | 1 | 2010 | 20 | 0.020 |
Why?
|
| Luminescent Measurements | 1 | 2010 | 60 | 0.020 |
Why?
|
| Microvilli | 1 | 2010 | 69 | 0.020 |
Why?
|
| Recombinant Proteins | 1 | 2014 | 1347 | 0.020 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2013 | 1284 | 0.020 |
Why?
|
| Case-Control Studies | 1 | 2017 | 3418 | 0.020 |
Why?
|
| Microscopy, Electron, Transmission | 1 | 2010 | 136 | 0.020 |
Why?
|
| Luciferases | 1 | 2010 | 129 | 0.020 |
Why?
|
| Interferon-gamma | 1 | 2012 | 534 | 0.020 |
Why?
|
| Incidence | 1 | 2018 | 3380 | 0.020 |
Why?
|
| Tissue Distribution | 1 | 2010 | 383 | 0.020 |
Why?
|
| Transcriptome | 1 | 2017 | 1125 | 0.020 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2010 | 424 | 0.020 |
Why?
|
| Microscopy, Confocal | 1 | 2010 | 367 | 0.020 |
Why?
|
| Epstein-Barr Virus Infections | 1 | 2011 | 293 | 0.020 |
Why?
|
| Tandem Mass Spectrometry | 1 | 2010 | 286 | 0.020 |
Why?
|
| Cell Survival | 1 | 2010 | 865 | 0.020 |
Why?
|
| Mice, Inbred BALB C | 1 | 2010 | 1046 | 0.020 |
Why?
|
| B7-1 Antigen | 1 | 2007 | 11 | 0.020 |
Why?
|
| Lipopolysaccharide Receptors | 1 | 2007 | 54 | 0.020 |
Why?
|
| Mutation | 1 | 2021 | 6229 | 0.020 |
Why?
|
| Neurons | 1 | 2017 | 1998 | 0.020 |
Why?
|
| Immunoglobulins | 1 | 2007 | 169 | 0.020 |
Why?
|
| Epitopes, T-Lymphocyte | 1 | 2007 | 130 | 0.020 |
Why?
|
| Antigens, CD | 1 | 2007 | 431 | 0.010 |
Why?
|
| Membrane Glycoproteins | 1 | 2007 | 420 | 0.010 |
Why?
|
| Dendritic Cells | 1 | 2007 | 448 | 0.010 |
Why?
|
| Risk Factors | 1 | 2017 | 10941 | 0.010 |
Why?
|
| Time Factors | 1 | 2010 | 6448 | 0.010 |
Why?
|
| United States | 1 | 2014 | 11658 | 0.010 |
Why?
|